Objectives

After participating in this educational activity, attendees should be able to:

1|Describe current guideline-recommended management of HFmrEF/HFpEF 
2|Evaluate efficacy and safety of finerenone for HFmrEF/HFpEF using the FINEARTS-HF trial 
3|Apply recent literature to clinical practice and explain finerenone's current place in therapy 
4|Describe the genetic modifications made to porcine kidneys to reduce immune rejection and improve compatibility with human recipients 
5|Analyze the immunosuppressive regimen and clinical outcomes observed following porcine kidney xenotransplantation in a human patient 
6|Evaluate the ethical, physiological, and clinical implications of xenotransplantation as a potential solution to the organ shortage crisis 

 

Presenter(s): 
 
Haley Whelchel, PharmD
PGY1 Pharmacy Resident
Baystate Medical Center
 
Madalyn Dankocsik, PharmD
PGY1 Pharmacy Resident
Baystate Medical Center
 
NameRoleFinancial Relationship DisclosuresDiscussion of
Unlabeled/Unapproved Uses of
Drugs/Devices in Presentation?
Madalyn Dankocsik, PharmD
Speaker/AuthorNo relevant relationships with ineligible companies to discloseNo
Haley Whelchel, PharmD
Speaker/AuthorNo relevant relationships with ineligible companies to discloseNo
Session date: 
10/27/2025 - 2:00pm to 3:00pm EDT
Add to calendar: 
  • 1.00 ACPE Contact Hours
  • 1.00 ACPE Technician contact hours
Please login or register to take this course.